Search
RTA 744
go.drugbank.com/drugs/DB05920InvestigationalRTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.
CYT007-TNFQb
go.drugbank.com/drugs/DB05758ExperimentalThe vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules. … CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.
Piroximone
go.drugbank.com/drugs/DB19750ExperimentalPiroximone is a small molecule drug. Piroximone has a monoisotopic molecular weight of 217.09 Da.
Categories: Compounds used in a research, industrial, or household settingMecrylate
go.drugbank.com/drugs/DB21343ExperimentalMecrylate is a small molecule drug. Mecrylate has a monoisotopic molecular weight of 111.03 Da.
Categories: Compounds used in a research, industrial, or household settingSodium sulfate
go.drugbank.com/drugs/DB09472ApprovedInvestigationalVet approvedSodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. … Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion
Methylisothiazolinone
go.drugbank.com/drugs/DB15884InvestigationalSynonyms: N-Methylisothiazolin-3-oneCategories: Compounds used in a research, industrial, or household settingGlyceryl laurate
go.drugbank.com/drugs/DB16635InvestigationalCategories: Compounds used in a research, industrial, or household settingBucrylate
go.drugbank.com/drugs/DB19727ExperimentalBucrylate is a small molecule drug. Bucrylate has a monoisotopic molecular weight of 153.08 Da.
Categories: Compounds used in a research, industrial, or household settingTorcetrapib
go.drugbank.com/drugs/DB06281InvestigationalTorcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination
Atibuclimab
go.drugbank.com/drugs/DB06546InvestigationalAtibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.